News | November 22, 2022
Merck to acquire Imago BioSciences for $1.35 bn
Acquisition expands Merck’s growing hematology portfolio
Acquisition expands Merck’s growing hematology portfolio
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
The two-day meeting in the city was organized in collaboration with the University of Birmingham, Christian Medical College Ludhiana, and Birmingham Clinical Trials Unit
Transformation to pure-play Innovative Medicines company nears completion
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Subscribe To Our Newsletter & Stay Updated
